Tanya Marie Turnock, LPN | |
510 2nd St S, Atwater, MN 56209-1015 | |
(651) 353-1229 | |
Not Available |
Full Name | Tanya Marie Turnock |
---|---|
Gender | Female |
Speciality | Licensed Practical Nurse |
Location | 510 2nd St S, Atwater, Minnesota |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1710277595 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164W00000X | Licensed Practical Nurse | L63536-5 (Minnesota) | Primary |
Mailing Address | Practice Location Address |
---|---|
Tanya Marie Turnock, LPN 510 2nd St S, Atwater, MN 56209-1015 Ph: (651) 353-1229 | Tanya Marie Turnock, LPN 510 2nd St S, Atwater, MN 56209-1015 Ph: (651) 353-1229 |
News Archive
Researchers from University Medical Centre Utrecht have been investigating the efficiency of vaccines against the alpha variant in the Netherlands.
Politico: "House Majority Leader Steny Hoyer said Tuesday that Democrats don't yet have the votes to pass a bill this week and that they're still talking with every single member of the caucus. He also told reporters during his half-hour weekly news conference that he hopes to have language for a reconciliation bill finalized later in the day and defended the possible use of the rules to deem the Senate bill passed without forcing members to actually take the uncomfortable vote to support it."
The time needed to genetically sequence the bacteria causing tuberculosis (Mtb) from patient samples has been reduced from weeks to days using a new technique developed by a UCL-led team. This could help health service providers to better treat disease, control transmission of this infection, and monitor outbreaks.
Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall survival (OS) and overall response rate (ORR) in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL, respectively) in the final analysis of the Phase III RESONATE™-2 (PCYC-1115) trial.
› Verified 4 days ago